echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Gastric Cancer: Effects of different anticoagulants on the risk of delayed bleeding after endoscopic mucosa peeling

    Gastric Cancer: Effects of different anticoagulants on the risk of delayed bleeding after endoscopic mucosa peeling

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Endoscopic mucosa subdural peeling (ESD) is a minimally invasive treatment for patients with lymph nodes negative and with early stage stomach cancer (EGC).
    , delayed bleeding after ESD is a frequent adverse event with an occurrence rate of between 3.1% and 6.5%.
    in an aging society, the number of patients taking anti-thrombosis as a preventive treatment against cardiovascular disease is increasing.
    Therefore, in the context of treatment with anticoagulants, including anticoagulants and plateboard drugs, the researchers observed that more and more patients were receiving ESD treatment, but that the increased risk of delayed bleeding had not been properly assessed.
    the effects of direct oral anticoagulants (DOAC) on preventing thrombosis remain unclear.
    , this study aims to explore the clinical effects of DOACs on delayed bleeding in patients with stomach cancer.
    reviewed clinical data on 728 patients who received anticoagulants and ESD for gastric tumors in 25 medical facilities in Japan.
    261 patients received DOAC treatment, including Dabiga (92), Devasaban (103), Apixaban (45) and Idosaban (21), while 467 patients received Huafarin treatment.
    all patients were counted for bleeding after ESD.
    results showed that 14 percent of patients taking DOAC had postoperative delayed bleeding, which was similar to the rate of patients receiving huafalin (18 percent).
    patients treated with the Dabiga group had significantly lower rates of delayed bleeding than those treated with huafalin, and lower than those treated with other DOAC.
    multi-factor analysis showed that age ≥65 years old, receiving a variety of anti-suppositive agents, removal of multiple lesions and lesions size ≥30 mm is an independent risk factor, and the suspension of anticoagulants is associated with reduced risk of bleeding.
    multivariable analysis in patients receiving DOAC, and the treatment of the dabiga group was associated with a significant reduction in the risk of delayed bleeding.
    doAC's effect on delayed bleeding varies from drug to drug, but D'Abiga group therapy minimizes the risk of delayed bleeding, the researchers concluded.
    oral anticoagulants to dhabiga group during perivironment may be a reasonable option to reduce the risk of delayed bleeding after gastric ESD.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.